Botulinum Toxin Treatment of Adult Muscle Stem Cells from Children with Cerebral Palsy and hiPSC-Derived Neuromuscular Junctions

Cells. 2023 Aug 15;12(16):2072. doi: 10.3390/cells12162072.

Abstract

Botulinum neurotoxin type-A (BoNT) injections are commonly used as spasticity treatment in cerebral palsy (CP). Despite improved clinical outcomes, concerns regarding harmful effects on muscle morphology have been raised, and the BoNT effect on muscle stem cells remains not well defined. This study aims at clarifying the impact of BoNT on growing muscles (1) by analyzing the in vitro effect of BoNT on satellite cell (SC)-derived myoblasts and fibroblasts obtained from medial gastrocnemius microbiopsies collected in young BoNT-naïve children (t0) compared to age ranged typically developing children; (2) by following the effect of in vivo BoNT administration on these cells obtained from the same children with CP at 3 (t1) and 6 (t2) months post BoNT; (3) by determining the direct effect of a single and repeated in vitro BoNT treatment on neuromuscular junctions (NMJs) differentiated from hiPSCs. In vitro BoNT did not affect myogenic differentiation or collagen production. The fusion index significantly decreased in CP at t2 compared to t0. In NMJ cocultures, BoNT treatment caused axonal swelling and fragmentation. Repeated treatments impaired the autophagic-lysosomal system. Further studies are warranted to understand the long-term and collateral effects of BoNT in the muscles of children with CP.

Keywords: BoNT cell treatment; adult muscle stem cells; cerebral palsy in young children; collagen; induced pluripotent stem cells; muscle microbiopsy; myogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Adult Stem Cells*
  • Botulinum Toxins*
  • Cerebral Palsy* / drug therapy
  • Child
  • Humans
  • Induced Pluripotent Stem Cells*
  • Muscles

Substances

  • Botulinum Toxins

Grants and funding

This project was funded by an internal KU Leuven grant (C24/18/103) and by Scientific Research Flanders (FWO; grant G0B4619N). D.C. was financed by internal funding of the KU Leuven Biomedical Science group: Fund for Translational Biomedical Research 2019. V.B. was funded by a mobility grant, Erasmus Placement 2021 from University of Turin (Italy). R.D. was supported by the internal KU Leuven grant (C24/18/103) and the postdoctoral mandate (PDM) type 1 of KU Leuven (PDMT1/21/037).